Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05307692 · ClinicalTrials.gov registry record · Phase 2

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

A Phase 2 study of Alzheimer Disease, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT05307692 is a Phase 2 study of Alzheimer Disease that has completed, run by Janssen Research & Development. The registered enrollment target is 88 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05307692, a Phase 2 study of Alzheimer Disease, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Placebo
  • DRUG Seltorexant

Study Locations (20)

Florida

  • Luminous Clinical Research - Homestead
  • Global Medical Institutes - Miami
  • Office of Emilio Mantero-Atienza, MD - Miami
  • Allied Biomedical Research Institute (ABRI), Inc - Miami
  • Quantix Research - Miami
  • Entrust Clinical Research - Miami
  • Florida International Research Center (FIRC) - Miami
  • P&S Research, LLC - Miami
  • IMIC Inc - Miami
  • Biovision Medical - Miami
  • South Florida Research Center Inc. - Miami Springs
  • Intercoastal Medical Group - Sarasota
  • Accel Clinical Research - Seminole

Georgia

  • Sonar Clinical Research - Atlanta
  • NeuroTrials Research Inc - Atlanta
  • Atlanta Center for Medical Research - Atlanta

Arizona

  • Medical Advancement Center of Arizona - Tempe

California

  • Sunwise Clinical Research - Lafayette

Louisiana

  • Ochsner Medical Center - New Orleans

Massachusetts

  • Boston Clinical Trials - Boston

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2022-05-19
Est. Completion 2023-11-10
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05307692

The ClinicalTrials.gov registry entry for NCT05307692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05307692 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Georgia, Arizona.

Frequently Asked Questions

What is clinical trial NCT05307692 about?

NCT05307692 is a clinical study titled "A Study of Seltorexant in Participants With Probable Alzheimer's Disease". The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation...

What is the current status of trial NCT05307692?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2022-05-19. Estimated completion is 2023-11-10.

What conditions does trial NCT05307692 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT05307692?

The interventions under investigation include: Placebo (DRUG), Seltorexant (DRUG).

Who is sponsoring clinical trial NCT05307692?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05307692 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.